Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Calcichew D3 · 1 trial · 1 indication
The PTH AUC(0-6) is a measure of the area under the serum concentration-time curve from 0 to 6 hours of parathyroid hormone.
Ca\^2+ Ae6 was calculated as the urine volume of the urine collected from 0 to 6 hours multiplied by the calcium concentration measured in urine.
| Arm | Type | Description |
|---|---|---|
| Noncarbonated Water + Calcichew D3 | EXPERIMENTAL | Noncarbonated water 200 milliliter (mL), orally, once daily on Days 1, 2 and 3 in period 1 (dummy treatment period) followed by Calcichew D3 500 milligram (mg)/1000 international units (IU) (Calcium 500 mg, chewable tablets and vitamin D3 1000 IU, chewable tablets), orally, once daily on Days 4, 5 and 6 in period 2 (study treatment period) of 6 days treatment period. |
| Name | Type | Description |
|---|---|---|
| Calcichew D3 | DRUG | Calcium 500 mg and vitamin D3 1000 IU chewable tablets |
| Noncarbonated Water | DRUG | Noncarbonated water 200 mL |
Inclusion Criteria: 1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements. 2. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, informed consent form and any requi...
Calcichew D3 is a chewable tablet containing calcium 500 mg and vitamin D3 1000 IU, studied in healthy volunteers. It is being investigated for its effect on intestinal calcium absorption. The drug is in Phase 1 clinical development and is not approved for any indication.
Calcichew D3 is developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. The company is conducting clinical research on this product in healthy volunteers.
Calcichew D3 is in Phase 1 clinical development. It is an investigational product and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and no active trials are currently ongoing.
Calcichew D3 has one completed clinical trial, NCT02338713, titled 'Effect of Calcium 500 mg and Vitamin D3 1000 IU Chewable Tablet on Intestinal Calcium Absorption.' This Phase 1 study enrolled 27 healthy volunteers in France, with participants aged 45 years and older.
Calcichew D3 is a specific chewable tablet formulation containing calcium 500 mg and vitamin D3 1000 IU. It is being studied for its effect on intestinal calcium absorption in healthy volunteers. The product is in Phase 1 clinical development.